What is CytomX Therapeutics's preferred stock?

CytomX Therapeutics (CTMX) reported preferred stock of $0 in Q1 2026.

What does preferred stock mean?

Equity securities with priority over common stock for dividends and liquidation proceeds, but typically without voting rights.

CytomX Therapeutics CTMX Preferred Stock

Preferred Stock at other companies

Janux TherapeuticsJANX

$0—

Allogene TherapeuticsALLO

$0—

Vir Biotechnology, Inc.VIR

$0—

Cullinan Therapeutics, Inc.CGEM

$0—

BioCryst PharmaceuticalsBCRX

$0—

OmerosOMER

$0—

Other financials

Income statement

See full

Revenue$10.3M-79.9%

Operating income-$19.7M-187%

Net income-$18.2M-178%

EPS (diluted)-$0.10-137%

Balance sheet

See full

Cash & equivalents$28.8M-39.4%

Total debt$2.9M-65.0%

Total equity$319.9M+1,177%

Total assets$359.4M+265%

Cash flow

See full

Operating cash flow-$25.5M-21.4%

CapEx--100%

Free cash flow-$25.5M-20.7%

Valuation

See full

Market cap$711.89M+94.8%

Enterprise value$685.92M+110%

P/S20×+17.6×

Profitability

See full

Operating margin-181.9%-206pp

Net margin-166.4%-195pp

FCF margin-225.6%-334pp

Returns & leverage

See full

Return on equity-34.3%—

Debt / equity0×-0.3×

Current ratio10.4×+8.7×

Where this comes from

Reported directly by CytomX Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:PreferredStockValue.

The official record: CytomX Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about CytomX Therapeutics's preferred stock.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI

Claude

Questions, answered.

What is CytomX Therapeutics's preferred stock?: CytomX Therapeutics (CTMX) reported preferred stock of $0 in Q1 2026.
What does preferred stock mean?: Equity securities with priority over common stock for dividends and liquidation proceeds, but typically without voting rights.